Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + rAd-p53 + vinorelbine
- Development stage
- Preclinical
- Lead developer
- Michigan State University
- Modality
- Gene Therapies, Small Molecules
- Administration
- Intravenous, Intratumoral
01
Overview
A combination therapy consisting of cisplatin (a platinum-based chemotherapy agent), rAd-p53 (a recombinant adenovirus carrying the p53 tumor suppressor gene), and vinorelbine (a vinca alkaloid chemotherapy agent). This regimen combines conventional chemotherapy with gene therapy approaches for cancer treatment.
02
Targets
DNATP53 (Cellular Tumor Antigen p53 R175H)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on cisplatin + rAd-p53 + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + rAd-p53 + vinorelbine.